<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2020000100009</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2020000100009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación de la seguridad y efectividad del intercambio de tenofovir disoproxilo a tenofovir alafenamida en vida real]]></article-title>
<article-title xml:lang="en"><![CDATA[Evaluation of the safety and effectiveness of the exchange of tenofovir disoproxil to tenofovir alafenamide in real life]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Raga Jiménez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez Martín]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferrando Piqueres]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[M Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Conde Giner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Usó Blasco]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Universitario de Castellón Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Castellón ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Complejo Asistencial de Soria Hospital Santa Bárbara Servicio de Farmacia]]></institution>
<addr-line><![CDATA[Soria ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital General Universitario de Castellón Servicio de Medicina Interna y Enfermedades Infecciosas ]]></institution>
<addr-line><![CDATA[Castellón ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>30</volume>
<numero>1</numero>
<fpage>28</fpage>
<lpage>32</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2020000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2020000100009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2020000100009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivos: Evaluar la seguridad y efectividad en vida real del intercambio en el tratamiento antirretroviral de tenofovir disoproxilo (TDF) a tenofovir alafenamida (TAF) en pacientes VIH.  Material y métodos: Estudio retrospectivo observacional durante 2017 en el que se incluyeron todos los pacientes del departamento de salud en tratamiento con TAF. Se evaluó la población obtenida y además se dividió en dos subgrupos no comparativos según el intercambio realizado: subgrupo 1, de elvitegravir/cobicistat/TDF/emtricitabina (EVG/c/TDF/FTC) a EVG/c/TAF/FTC; y subgrupo 2, de TDF/FTC a TAF/FTC. Para la seguridad se midió antes y después del intercambio: creatinina (Cr), urea y velocidad de filtrado glomerular (VFG). Para la efectividad carga viral (CV) y linfocitos CD4. La CV se tomó como variable binaria interpretándose como pacientes respondedores (&lt;20 copias/mL) o no. Las variables numéricas se expresaron en medianas y las cualitativas en porcentaje e intervalo intercuartílico (IQR). Las pruebas utilizadas fueron W de Wilcoxon y chi cuadrado respectivamente.  Resultados: Se obtuvo una muestra de 55 pacientes en los que hubo una variación antes y después del cambio de Cr=0,9 mg/dL (IQR=0,8-1) a Cr=0,8 mg/dL (IQR=0,7-0,9) (p&lt;0,001), de urea=29 mg/dL (IQR=24-36) a urea=28 mg/dL (25-34,5) (p=0,06) y de VFG=92,8 mL/min (79,3-102,1) a VFG=103,6 (IQR=95,9-111,1) (p&lt;0,001). En cuanto a efectividad hubo un incremento desde el 51% al 59,9% (p=0,821) y para CD4 de 668 CD4/mcL (IQR=496-824) a 684 CD4/mcL (IQR=611-807) (p=0,084). Los resultados por subgrupos fueron similares.  Conclusiones: Este estudio muestra en una misma población en vida real, que tras el cambio en la sal de tenofovir se mantiene un buen perfil de seguridad con mejora de parámetros analíticos de la función renal sin perjuicio en la efectividad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Objective: To assess safety and effectiveness in real world of the switch in the antiretroviral treatment (ART) of tenofovir disoproxil (TDF) to tenofovir alafenamide (TAF) in HIV patients.  Material and methods: Observational retrospective study during 2017 in which all the patients of the health department under treatment with TAF were included. The population obtained was evaluated and also divided into two non-comparative subgroups according to the switch performed: subgroup 1, from elvitegravir/cobicistat/TDF/emtricitabine (EVG/c/TDF/FTC) to EVG/c/TAF/FTC; and subgroup 2, from TDF/FTC to TAF/FTC. To evaluate safety, before and after the switch, was measured: creatinine (Cr), urea and glomerular filtration rate (GFR). To evaluate effectiveness was measured viral load (VL) and CD4 lymphocytes (CD4). VL was interpreted as binary variable: responder patients (&lt;20 copies/mL) or non-responder patients. Numerical variables were expressed as medians (Md) and qualitative variables as percentage and interquartile interval (IQR). The statistical tests used were W of Wilcoxon and chi square respectively.  Results: A sample of 55 patients was obtained. There was a variation, before and after the switch, of Cr=0.9 mg/dL (IQR=0.8-1) to Cr=0.8 mg/dL (IQR=0.7-0.9) (p&lt;0.001), from urea=29 mg/dL (IQR=24-36) to urea=28 mg/dL (IQR=25-34.5) (p=0.06) and from GFR=92.8 mL/min (IQR=79.3-102.1) to GRT=103.6 (IQR=95.9-111.1) (p&lt;0.001). In terms of effectiveness there was an increase from 51% to 59.9% (p=0.821) responding patients and for CD4 from 668 CD4/mcL (IQR=446-824) to 684 CD4/mcL (IQR=611-807) (p=0.058). The results by subgroups were similar.  Conclusions: This study showed in real world after the change of tenofovir salt within the same population that a good safety profile is manteined with an improvement of analytical parameters of renal function without affecting its effectiveness.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[VIH]]></kwd>
<kwd lng="es"><![CDATA[tenofovir alafenamida]]></kwd>
<kwd lng="es"><![CDATA[función renal]]></kwd>
<kwd lng="en"><![CDATA[HIV]]></kwd>
<kwd lng="en"><![CDATA[tenofovir alafenamide]]></kwd>
<kwd lng="en"><![CDATA[renal function]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Hendry]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Nitsch]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tenofovir-associated kidney toxicity in HIV-infected patients: A review of the evidence]]></article-title>
<source><![CDATA[American Journal of Kidney Diseases]]></source>
<year>2011</year>
<volume>57</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>773-80</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arribas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sax]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wohl]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[McCallister]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results]]></article-title>
<source><![CDATA[Journal of Acquired Immune Deficiency Syndromes]]></source>
<year>2017</year>
<volume>75</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>211-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sax]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Wohl]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Post]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[DeJesus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Saag]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McCallister]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2015</year>
<volume>385</volume>
<numero>9987</numero>
<issue>9987</issue>
<page-range>2606-15</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raffi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Orkin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Slama]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gallant]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Daar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rhee]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults]]></article-title>
<source><![CDATA[Journal of Acquired Immune Deficiency Syndromes]]></source>
<year>2017</year>
<volume>75</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>226-31</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dejesus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Segal-Maurer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ramgopal]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Margot]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McCallister]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate - to a tenofovir alafenamide-based regimen through 96 weeks of treatment]]></article-title>
<source><![CDATA[AIDS Research and Human Retroviruses]]></source>
<year>2018</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>337-42</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Podany]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Bares]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Havens]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dyavar]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[O'Neill]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Scarsi]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2018</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>761-5</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Polo]]></surname>
<given-names><![CDATA[RME]]></given-names>
</name>
</person-group>
<source><![CDATA[Documento de consenso de GeSIDA/Plan Nacional sobre el SIDA respecto al tratamiento]]></source>
<year>2018</year>
<numero>75</numero>
<issue>75</issue>
<publisher-name><![CDATA[GeSIDA Gobierno de España]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="">
<source><![CDATA[Documento de Consenso sobre Profilaxis postexposición ocupacional y no ocupacional en relación con el VIH, VHB y VHC en adultos y niños]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levey]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Castro III]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[HI]]></given-names>
</name>
<name>
<surname><![CDATA[Lente]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A New equation to estimate glomerular filtration rate disclosure of conflicts of interest: We have received confirmation from Drs]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2009</year>
<volume>150</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>604-12</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castaño Bilbao]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Slon Roblero]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[García-Fernández]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudios de función renal: función glomerular y tubular. Análisis de la orina]]></article-title>
<source><![CDATA[NefroPlus]]></source>
<year>2009</year>
<volume>2</volume>
<page-range>17-30</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
